Showing results (101-110 of 274) with videos related to
Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancerChristina M Annunziata, Lilach Kleinberg, Ben Davidson, et al.Journal of Pharmaceutical and Biomedical Analysis|July 14, 2020
Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MSJulianne L Holleran, Robert A Parise, Jianxia Guo, et al.Journal of the National Cancer Institute|November 11, 2015
Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer InstituteJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.Cancer Chemotherapy and Pharmacology|December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Both protein activation and gene expression are involved in early vascular tube formation in vitroAndrew D Grove, Vinay V Prabhu, B Lynn Young, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2015
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeLesley Seymour, Susan Groshen, Gary L Rosner, et al.Investigational New Drugs|February 29, 2012
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsChristina M Annunziata, Elise C Kohn, Patricia LoRusso, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 19, 2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)Suresh S Ramalingam, Chandra P Belani, Philip C Mack, et al.Cancer Chemotherapy and Pharmacology|May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactionsLawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve AccrualHolly A Massett, Grace Mishkin, Larry Rubinstein, et al.Pageof 28